medigraphic.com
Revista Médica Sinergia

2020, Number 04

<< Back Next >>

Revista Médica Sinergia 2020; 5 (04)

Influence of Alzheimer's disease on synaptic neurotransmission systems

Álvarez CA, Rodríguez AJM, Salas BA

Language: Spanish
References: 56
Page: 1-16
PDF size: 199.25 Kb.


ABSTRACT

Alzheimer's disease represents the most frequent dementia worldwide. It is characterized by being a neurodegenerative pathology with a complex pathophysiology in which multiple factors are involved. Since the main organ affected is the brain, it usually manifests with cognitive, behavioral and functional alterations, as well as histopathological alterations that lead to the levels of some of the main neurotransmitters being affected, which can provide information about the disease and the patient's condition. In addition, because the disease can begin long before the first symptoms occur, the variation in the different neurotransmitters could provide information at the time of making a diagnosis or assessing the evolution of the disease.


REFERENCES

  1. Carazo ET, Blanco MN. Abordaje diagnóstico y terapéutico de la demencia en atención primaria. SEMERGENde Familia Medicina. 2001;27(11):575-586. https://doi.org/10.1016/S1138-3593(01)74030-0

  2. Herrera-Rivero M, Hernández-Aguilar ME, Manzo J, Aranda-Abreu GE. Enfermedad de Alzheimer: inmunidad y diagnóstico. Revista de neurología. 2010;51(3):153-164. https://doi.org/10.33588/rn.5103.2009531

  3. Maurer K, Volk S, Gerbaldo H. Auguste D and Alzheimer's disease. The Lancet. 1997;349(9064):1546-1549. https://doi.org/10.1016/S0140-6736(96)10203-8

  4. Alzheimer A. Über eigenartige Krankheitsfälle des späteren Alters: (On certain peculiar diseases of old age. Hist Psychiatry. marzo de 1991;2(5):74-101. https://doi.org/10.1177/0957154X9100200506

  5. Querfurth HW, LaFerla FM. Mechanisms of disease. N Engl J Med. 2010;362(4):329-344. https://doi.org/10.1056/NEJMra0909142

  6. Scheff SW, Price DA, Schmitt FA, DeKosky ST, Mufson EJ. Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology. 1 de mayo de 2007;68(18):1501-8. https://doi.org/10.1212/01.wnl.0000260698.46517.8f

  7. Lane CA, Hardy J, Schott JM. Alzheimer's disease. Eur J Neurol. enero de 2018;25(1):59-70. https://doi.org/10.1111/ene.13439

  8. Altuna-Azkargorta M, Mendioroz-Iriarte M. Biomarcadores sanguíneos en la enfermedad de Alzheimer. Neurología. 2018; https://doi.org/10.1016/j.nrl.2018.03.006

  9. Scheltens P, Blennow K, Breteler MMB, de Strooper B, Frisoni GB, Salloway S, et al. Alzheimer's disease. The Lancet. julio de 2016;388(10043):505-17. https://doi.org/10.1016/S0140-6736(15)01124-1

  10. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Rimmler JB, et al. Apolipoprotein E, survival in Alzheimer's disease patients, and the competing risks of death and Alzheimer's disease. Neurology. 1 de julio de 1995;45(7):1323-8. https://doi.org/10.1212/WNL.45.7.1323

  11. Verghese PB, Castellano JM, Holtzman DM. Apolipoprotein E in Alzheimer's disease and other neurological disorders. The Lancet Neurology. marzo de 2011;10(3):241-52. https://doi.org/10.1016/S1474-4422(10)70325-2

  12. González Rodríguez VM, Martín Martín C, Martín Prieto M, González Moneo MJ, García de Blas González F, Riu Subirana S. La enfermedad de Alzheimer. SEMERGEN - Medicina de Familia. enero de 2004;30(1):18-33. https://doi.org/10.1016/S1138-3593(04)74266-5

  13. Rhein V, Eckert A. Effects of Alzheimer's amyloid-beta and tau protein on mitochondrial function-role of glucose metabolism and insulin signalling. Archives of Physiology and Biochemistry. enero de 2007;113(3):131- 41.https://doi.org/10.1080/13813450701572288

  14. Reynaldo Fernández G, Pardo Andréu G, Guevara García M, Cascudo Barral N, Carrasco García MR. Teorías acerca de los mecanismos celulares y moleculares en la enfermedad de Alzheimer. Revista Cubana de Medicina. 2008;47(3):0-0.

  15. Allegri RF, Arizaga RL, Bavec CV, Colli LP, Demey I, Fernández MC, et al. Enfermedad de Alzheimer. Guía de práctica clínica. Neurología Argentina. 2011;3(2):120-137. https://doi.org/10.1016/S1853-0028(11)70026-X

  16. Gil Gregorio P. Criterios diagnósticos. Beneficios del diagnóstico precoz. Revista Española de Geriatría y Gerontología. junio de 2016;51:7-11. https://doi.org/10.1016/S0211-139X(16)30137-8

  17. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β- peptide. Nature reviews Molecular cell biology. 2007;8(2):101. https://doi.org/10.1038/nrm2101

  18. Mattson MP. Pathways towards and away from Alzheimer's disease. Nature. 2004;430(7000):631.https://doi.org/10.1038/nature02621

  19. Rossi G, Dalprà L, Crosti F, Lissoni S, Sciacca FL, Catania M, et al. A new function of microtubule-associated protein tau: Involvement in chromosome stability. Cell Cycle. 15 de junio de 2008;7(12):1788- 94.https://doi.org/10.4161/cc.7.12.6012

  20. Robles A, Del Ser T, Alom J, Pena-Casanova J. Propuesta de criterios para el diagnóstico clínico del deterioro cognitivo ligero, la demencia y la enfermedad de Alzheimer. Neurología. 2002;17(1):17-32.

  21. Dubois B, Feldman HH, Jacova C, DeKosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. The Lancet Neurology. agosto de 2007;6(8):734-46. https://doi.org/10.1016/S1474-4422(07)70178-3

  22. López-Álvarez J, Agüera-Ortiz LF. Nuevos criterios diagnósticos de la demencia y la enfermedad de Alzheimer: una visión desde la psicogeriatría. Psicogeriatría. 2015;5(1):3-14.

  23. Lister JP, Barnes CA. Neurobiological Changes in the Hippocampus During Normative Aging. Arch Neurol [Internet]. 1 de julio de 2009 [citado 11 de agosto de 2019];66(7). https://doi.org/10.1001/archneurol.2009.125

  24. Masliah E, Mallory M, Alford M, DeTeresa R, Hansen LA, McKeel DW, et al. Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology. 9 de enero de 2001;56(1):127- 9.https://doi.org/10.1212/WNL.56.1.127

  25. Kandimalla R, Reddy PH. Therapeutics of neurotransmitters in Alzheimer's disease. Journal of Alzheimer's Disease. 2017;57(4):1049-1069.https://doi.org/10.3233/JAD-161118

  26. Mesulam M-M, Van Hoesen GW. Acetylcholinesterase-rich projections from the basal forebrain of the rhesus monkey to neocortex. Brain research. 1976;109(1):152-157.https://doi.org/10.1016/0006-8993(76)90385-1

  27. Manzano-Palomo S, De la Morena-Vicente MA, Barquero MS. Neurotransmisores en la enfermedad de Alzheimer. Rev Neurol. 2006;42(6):350-353. https://doi.org/10.33588/rn.4206.2005219

  28. H Ferreira-Vieira T, M Guimaraes I, R Silva F, M Ribeiro F. Alzheimer's disease: targeting the cholinergic system. Current neuropharmacology. 2016;14(1):101-115. https://doi.org/10.2174/1570159X13666150716165726

  29. Strada O, Vyas S, Hirsch EC, Ruberg M, Brice A, Agid Y, et al. Decreased choline acetyltransferase mRNA expression in the nucleus basalis of Meynert in Alzheimer disease: an in situ hybridization study. Proceedings of the National Academy of Sciences. 15 de octubre de 1992;89(20):9549- 53.https://doi.org/10.1073/pnas.89.20.9549

  30. Gazulla J, Cavero-Nagore M. Glutamato y enfermedad de Alzheimer. Revista de neurología. 2006;42:427-32. https://doi.org/10.33588/rn.4207.2005223

  31. Ruiz-Mejía AF, Pérez-Romero GE, Ángel-Macías MA. Ataque cerebrovascular isquémico: fisiopatología desde el sistema biomédico y su equivalente en la medicina tradicional china. Rev Fac Med. 1 de enero de 2017;65(1):137-44. https://doi.org/10.15446/revfacmed.v65n1.57508

  32. Flores-Soto ME, Chaparro-Huerta V, Escoto-Delgadillo M, Vazquez-Valls E, González-Castañeda RE, Beas- Zarate C. Estructura y función de las subunidades del receptor a glutamato tipo NMDA. Neurología. 2012;27(5):301-310. https://doi.org/10.1016/j.nrl.2011.10.014

  33. Esposito Z, Belli L, Toniolo S, Sancesario G, Bianconi C, Martorana A. Amyloid β, Glutamate, Excitotoxicity in Alzheimer's Disease: Are We on the Right Track? CNS Neurosci Ther. agosto de 2013;19(8):549- 55.https://doi.org/10.1111/cns.12095

  34. Revett TJ, Baker GB, Jhamandas J, Kar S. Glutamate system, amyloid β peptides and tau protein: functional interrelationships and relevance to Alzheimer disease pathology. Journal of psychiatry & neuroscience: JPN. 2013;38(1):6.https://doi.org/10.1503/jpn.110190

  35. Rammes G, Hasenjäger A, Sroka-Saidi K, Deussing JM, Parsons CG. Therapeutic significance of NR2Bcontaining NMDA receptors and mGluR5 metabotropic glutamate receptors in mediating the synaptotoxic effects of β-amyloid oligomers on long-term potentiation (LTP) in murine hippocampal slices. Neuropharmacology. mayo de 2011;60(6):982-90.https://doi.org/10.1016/j.neuropharm.2011.01.051

  36. Domingues A, Almeida S, Dacruzesilva E, Oliveira C, Rego A. Toxicity of β-amyloid in HEK293 cells expressing NR1/NR2A or NR1/NR2B N-methyl-d-aspartate receptor subunits. Neurochemistry International. mayo de 2007;50(6):872-80. https://doi.org/10.1016/j.neuint.2007.03.001

  37. Chen J, Herrup K. Glutamine as a Potential Neuroprotectant in Alzheimer's Disease. En: Diet and Nutrition in Dementia and Cognitive Decline. Elsevier; 2015. p. 761-771. https://doi.org/10.1016/B978-0-12-407824-6.00070-7

  38. Robinson SR. Neuronal expression of glutamine synthetase in Alzheimer's disease indicates a profound impairment of metabolic interactions with astrocytes. Neurochemistry International. abril de 2000;36(4-5):471- 82.https://doi.org/10.1016/S0197-0186(99)00150-3

  39. Butterfield DA, Poon HF, St. Clair D, Keller JN, Pierce WM, Klein JB, et al. Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: Insights into the development of Alzheimer's disease. Neurobiology of Disease. mayo de 2006;22(2):223- 32.https://doi.org/10.1016/j.nbd.2005.11.002

  40. Olabarria M, Noristani HN, Verkhratsky A, Rodríguez JJ. Age-dependent decrease in glutamine synthetase expression in the hippocampal astroglia of the triple transgenic Alzheimer's disease mouse model: mechanism for deficient glutamatergic transmission? Mol Neurodegeneration. 2011;6(1):55. https://doi.org/10.1186/1750- 1326-6-55

  41. Le Prince G, Delaere P, Fages C, Lefrançois T, Touret M, Salanon M, et al. Glutamine synthetase (GS) expression is reduced in senile dementia of the Alzheimer type. Neurochemical research. 1995;20(7):859- 862.https://doi.org/10.1007/BF00969698

  42. Wu Z, Guo Z, Gearing M, Chen G. Tonic inhibition in dentate gyrus impairs long-term potentiation and memory in an Alzheimer's disease model. Nature communications. 2014;5:4159.https://doi.org/10.1038/ncomms5159

  43. Sanacora G, Fenton LR, Fasula MK, Rothman DL, Levin Y, Krystal JH, et al. Cortical γ-aminobutyric acid concentrations in depressed patients receiving cognitive behavioral therapy. Biological psychiatry. 2006;59(3):284-286 https://doi.org/10.1016/j.biopsych.2005.07.015

  44. Walia V, Gilhotra N. GABAergic Influence in the Antidepressant Effect of Fluoxetine in Unstressed and Stressed Mice. J App Pharma Sci [Internet]. 2017 [citado 21 de agosto de 2019]; Disponible en: http://www.japsonline.com/admin/php/uploads/2203_pdf.pdf

  45. Ulrich D. Amyloid-β impairs synaptic inhibition via GABAA receptor endocytosis. Journal of Neuroscience. 2015;35(24):9205-9210.https://doi.org/10.1523/JNEUROSCI.0950-15.2015

  46. Garcia-Alloza M, Tsang SW, Gil-Bea FJ, Francis PT, Lai MK, Marcos B, et al. Involvement of the GABAergic system in depressive symptoms of Alzheimer's disease. Neurobiology of Aging. agosto de 2006;27(8):1110- 7.https://doi.org/10.1016/j.neurobiolaging.2005.06.003

  47. Mario ÁS, Ivonne P, Arnoldo PS, Marilet ÁS, Lázaro Á. Fisiopatología de la enfermedad de Alzheimer. Rev Mex Neuroci. 2008; 9(3): 196-201

  48. Lapuente FR, Navarro JPS. CAMBIOS NEUROPSICOLÓGICOS ASOCIADOS AL ENVEJECIMIENTO NORMAL. 1. 1998;14(1):27-43.

  49. Bondareff W, Mountjoy CQ, Roth M. Loss of neurons of origin of the adrenergic projection to cerebral cortex (nucleus locus ceruleus) in senile dementia. Neurology. 1982;32(2):164-164. https://doi.org/10.1212/WNL.32.2.164

  50. Orozco AR, Briseño RE, De Robles XF, Wong GACO. Neuroimagen en enfermedad de Alzheimer y otras demencias. ARCHIVOS DE NEUROCIENCIAS. 2016;45.

  51. Gallant M, Rak M, Szeghalmi A, Del Bigio MR, Westaway D, Yang J, et al. Focally Elevated Creatine Detected in Amyloid Precursor Protein (APP) Transgenic Mice and Alzheimer Disease Brain Tissue. J Biol Chem. 6 de enero de 2006;281(1):5-8.https://doi.org/10.1074/jbc.C500244200

  52. McLaurin J, Golomb R, Jurewicz A, Antel JP, Fraser PE. Inositol Stereoisomers Stabilize an Oligomeric Aggregate of Alzheimer Amyloid β Peptide and Inhibit Aβ-induced Toxicity. J Biol Chem. 16 de junio de 2000;275(24):18495-502.https://doi.org/10.1074/jbc.M906994199

  53. Orellana DI, Lujambio DPS, Dhyver DC, Díaz DM, Gil DA, Jasso DRR, et al. TRABAJOS EN CARTEL. XXXVI CURSO ANUAL DE RADIOLOGÍA SMRI. :5.

  54. Voevodskaya O, Sundgren PC, Strandberg O, Zetterberg H, Minthon L, Blennow K, et al. Myo-inositol changes precede amyloid pathology and relate to APOE genotype in Alzheimer disease. Neurology. 2016;86(19):1754- 1761.https://doi.org/10.1212/WNL.0000000000002672

  55. Kantarci K. Proton MRS in mild cognitive impairment [Internet]. Journal of Magnetic Resonance Imaging. 2013 [citado 31 de agosto de 2019]. Disponible en: https://onlinelibrary.wiley.com/doi/abs/10.1002/jmri.23800

  56. Modrego PJ, Pina MA, Fayed N, Díaz M. Changes in metabolite ratios after treatment with rivastigmine in Alzheimer's disease. CNS drugs. 2006;20(10):867-877. https://doi.org/10.2165/00023210-200620100-00006




2020     |     www.medigraphic.com